Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval In EU
Zacks Investment Research | Jan 23, 2020 09:17PM ET
This week marked the beginning of the fourth-quarter 2019 earnings season with J&J (NYSE:JNJ) announcing mixed results. The European Commission granted approval to two new drugs, Roche’s (OTC:RHHBY) lymphoma drug, Polivy and Novartis’ (NYSE:NVS) Mayzent for secondary progressive multiple sclerosis (SPMS).
Recap of the Week’s Most Important Stories:
J&J’s Mixed Fourth-Quarter Earnings: J&J’s fourth-quarter results were mixed as it beat estimates for Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last four trading sessions.
Last week, Glaxo recorded the maximum gain (1.4%) while Merck declined the most (2.9%).
In the past six months, Bristol-Myers has risen the most (47.2%) while Pfizer (NYSE:PFE) lost the maximum (4.6%).
(See the last pharma stock roundup here: Original post
Get The News You Want